2012 Scrip 100: Love for the unloved – reinventing Foscavir
This article was originally published in Scrip
Executive Summary
The tail end of the lifecycle does not have to be the closing chapter for pharmaceutical products. From its launch in the late 1980s until 2010, AstraZeneca marketed the antiviral Foscavir (foscarnet sodium) as a treatment for HIV/AIDS-related cytomegalovirus (CMV) infections and herpes.